Shield Therapeutics (STX) is a speciality pharmaceutical company with an approved product, Feraccru, for the treatment of iron deficiency anaemia (IDA) caused by inflammatory bowel disease (IBD). Feraccru has already been launched in the UK and Germany. Upcoming readout of a pivotal Phase III trial in chronic kidney disease (CKD) could allow sales into the US whilst a Head to Head study (H2H) would strengthen the EU reimbursement case in 2018. Feraccru offers clear clinical benefits to a poor
07 Sep 2017
Iron tired of being tired all the time
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Iron tired of being tired all the time
Shield Therapeutics Plc (STX:LON) | 1.5 0 3.4% | Mkt Cap: 11.9m
- Published:
07 Sep 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
24
Shield Therapeutics (STX) is a speciality pharmaceutical company with an approved product, Feraccru, for the treatment of iron deficiency anaemia (IDA) caused by inflammatory bowel disease (IBD). Feraccru has already been launched in the UK and Germany. Upcoming readout of a pivotal Phase III trial in chronic kidney disease (CKD) could allow sales into the US whilst a Head to Head study (H2H) would strengthen the EU reimbursement case in 2018. Feraccru offers clear clinical benefits to a poor